PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30538568-5	2018	For cases with comparably low DPD activity, advisable primary and subsequent dose adjustment of 5-fluorouracil based on plasma 5-fluorouracil levels may be a practical strategy for reducing the occurrence of adverse reactions for personalized treatment of the UGT1A1*6 or UGT1A1*28 heterozygous type.	Fluorouracil	96-110	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	260-266	
30538568-5	2018	For cases with comparably low DPD activity, advisable primary and subsequent dose adjustment of 5-fluorouracil based on plasma 5-fluorouracil levels may be a practical strategy for reducing the occurrence of adverse reactions for personalized treatment of the UGT1A1*6 or UGT1A1*28 heterozygous type.	Fluorouracil	96-110	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	272-278	
30538568-5	2018	For cases with comparably low DPD activity, advisable primary and subsequent dose adjustment of 5-fluorouracil based on plasma 5-fluorouracil levels may be a practical strategy for reducing the occurrence of adverse reactions for personalized treatment of the UGT1A1*6 or UGT1A1*28 heterozygous type.	Fluorouracil	127-141	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	260-266	
30538568-5	2018	For cases with comparably low DPD activity, advisable primary and subsequent dose adjustment of 5-fluorouracil based on plasma 5-fluorouracil levels may be a practical strategy for reducing the occurrence of adverse reactions for personalized treatment of the UGT1A1*6 or UGT1A1*28 heterozygous type.	Fluorouracil	127-141	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	272-278